Medical center is evaluating of an Automated Physician-Directed Messaging on Patient Engagement in the Digital Diabetes Prevention Program
NYU Langone Health is recruiting patients for the clinical trial of Evaluation of an Automated Physician-Directed Messaging on Patient Engagement in the Digital Diabetes Prevention Program.
This study aims to understand the effects of automated physician directed messaging on patient engagement in the digital diabetes prevention program (dDPP). The messages are tailored to patient engagement levels based on established engagement thresholds, which are based on the patient's use of the dDPP application. The system is designed to minimize work for providers by sending automated targeted messages to patients to potentially increase engagement, prevent onset of diabetes and improve clinical outcomes. The patients in the study are automatically nudged using a combination of text messaging and MyChart messaging.
The researchers plan that February 1, 2021 will be the study start date. The indicative completion of the clinical trial will be expected in September 2022.
The study will take place at the NYU Langone Health, New York, New York, United States.
Among the inclusion conditions appear:
- 18 years or older, BMI ≥ 25 kg/m2 (> 22 kg/m2 if self-identified as Asian).
- A diagnosis of prediabetes (either diagnosis of prediabetes or an HbA1C level of 5.7%-6.4% in past 12 months) or diabetes risk factors (BMI ≥ 25 kg/m2 or > 22 kg/m2 if self-identified as Asian.
- Safe to engage in moderate physical exercise (as determined by their PCP).
- Sufficient English to be able to complete the enrollment process.
- Has app-capable device with data to use the dDPP application and receive text messages.
The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT04773834
Clinical Research News
Upcoming Clinical Trials
NCT04847206Not yet recruitingConditions: Healthy
NCT04847232Not yet recruitingEffect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)Conditions: Hyperkalemia
NCT04847245Not yet recruitingEsketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive DisorderConditions: Chronic Visceral Pain; Major Depressive Disorder
NCT04847271Not yet recruitingConditions: Obesity, Childhood
NCT04847297Not yet recruitingConditions: Pancreatic Cancer
NCT04847310Not yet recruitingCost-effectiveness Evaluation of the Individual vs Group Transdiagnostic Psychological Treatment for Emotional Disorders in Primary CareConditions: Emotional Disorder; Depression; Somatoform Disorders; Anxiety Disorders
NCT04847401Not yet recruitingConditions: Irritable Bowel Syndrome
NCT04847453Not yet recruitingVenetoclax, Ixazomib Citrate and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain AmyloidosisConditions: Recurrent AL Amyloidosis; Refractory AL Amyloidosis
NCT04847466Not yet recruitingA Phase II Study of Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck CancerConditions: Gastroesophageal Junction (GEJ) Cancers; Advanced HNSCC
NCT04847479Not yet recruitingConditions: Covid19